Dr. Steve N. Slilaty
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Dr. Steve N. Slilaty
Dr. Steve N. Slilaty is recorded as CEO at Sunshine Biopharma Inc. (SBFM). Sunshine Biopharma Inc. reported in an 8-K filed January 30, 2024 that Dr. Steve N. Slilaty was appointed President and Chief Executive Officer, effective January 25, 2024. The proxy statement of Sunshine Biopharma Inc. reports total compensation of $560,000 for Dr. Steve N. Slilaty in fiscal 2023, including a base salary of $378,000. Disclosed compensation is on record for 3 fiscal years.
“At the meeting the following persons were elected to the following positions: Dr. Steve N. Slilaty | President and Chief Executive Officer”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
Start not stated–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Sunshine Biopharma Inc.
Other people whose current roles at this company are on record from its filings.
- Camille Sebaaly CFO
- Mr. Camille Sebaaly CFO
- Marc Beaudoin COO
- Mr. Marc Beaudoin COO
- Andrew Telsey Board Member
- Dr. Andrew Keller Board Member
- Dr. Rabi Kiderchah Board Member
- JD Kish Board Member
- Mr. David Natan Board Member
- Rabi Kiderchah Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2023 | Sunshine Biopharma Inc. (SBFM) | Chief Executive Officer and Director | $378,000 | $560,000 |
| 2022 | Sunshine Biopharma Inc. (SBFM) | Chief Executive Officer and Director | $360,000 | $370,000 |
| 2021 | Sunshine Biopharma Inc. (SBFM) | Chief Executive Officer and Director | $156,380 | $462,380 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.